CN1780623B - Pten抑制剂或maxi-k通道开放剂 - Google Patents

Pten抑制剂或maxi-k通道开放剂 Download PDF

Info

Publication number
CN1780623B
CN1780623B CN2004800111403A CN200480011140A CN1780623B CN 1780623 B CN1780623 B CN 1780623B CN 2004800111403 A CN2004800111403 A CN 2004800111403A CN 200480011140 A CN200480011140 A CN 200480011140A CN 1780623 B CN1780623 B CN 1780623B
Authority
CN
China
Prior art keywords
maxi
pten
cell
mice
cilostazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800111403A
Other languages
English (en)
Chinese (zh)
Other versions
CN1780623A (zh
Inventor
洪起焕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to CN201010130082.3A priority Critical patent/CN101829116B/zh
Publication of CN1780623A publication Critical patent/CN1780623A/zh
Application granted granted Critical
Publication of CN1780623B publication Critical patent/CN1780623B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2004800111403A 2003-02-25 2004-02-24 Pten抑制剂或maxi-k通道开放剂 Expired - Fee Related CN1780623B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201010130082.3A CN101829116B (zh) 2003-02-25 2004-02-24 Pten抑制剂或maxi-k通道开放剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44943503P 2003-02-25 2003-02-25
US60/449,435 2003-02-25
US44958903P 2003-02-26 2003-02-26
US60/449,589 2003-02-26
PCT/JP2004/002146 WO2004075897A1 (en) 2003-02-25 2004-02-24 Pten inhibitor or maxi-k channels opener

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010130082.3A Division CN101829116B (zh) 2003-02-25 2004-02-24 Pten抑制剂或maxi-k通道开放剂

Publications (2)

Publication Number Publication Date
CN1780623A CN1780623A (zh) 2006-05-31
CN1780623B true CN1780623B (zh) 2011-09-14

Family

ID=32930512

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800111403A Expired - Fee Related CN1780623B (zh) 2003-02-25 2004-02-24 Pten抑制剂或maxi-k通道开放剂
CN201010130082.3A Expired - Fee Related CN101829116B (zh) 2003-02-25 2004-02-24 Pten抑制剂或maxi-k通道开放剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201010130082.3A Expired - Fee Related CN101829116B (zh) 2003-02-25 2004-02-24 Pten抑制剂或maxi-k通道开放剂

Country Status (19)

Country Link
US (3) US7825130B2 (https=)
EP (1) EP1599205B1 (https=)
JP (3) JP4590397B2 (https=)
KR (1) KR101031163B1 (https=)
CN (2) CN1780623B (https=)
AR (1) AR043379A1 (https=)
AT (1) ATE345800T1 (https=)
AU (1) AU2004216340B9 (https=)
BR (1) BRPI0407832A (https=)
CA (1) CA2515590C (https=)
CY (1) CY1106294T1 (https=)
DE (1) DE602004003348T2 (https=)
DK (1) DK1599205T3 (https=)
ES (1) ES2276282T3 (https=)
MX (1) MXPA05008996A (https=)
MY (1) MY136863A (https=)
PT (1) PT1599205E (https=)
TW (1) TWI323660B (https=)
WO (1) WO2004075897A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
KR101441725B1 (ko) * 2007-05-22 2014-09-18 오츠카 세이야쿠 가부시키가이샤 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제
AR067746A1 (es) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
CN101932331B (zh) * 2008-01-17 2012-10-24 刘奎 卵泡体外成熟方法
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
WO2009117387A2 (en) * 2008-03-17 2009-09-24 The Trustees Of Columbia University In The City Of New York Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
US8367352B2 (en) 2008-06-06 2013-02-05 Children's Medical Center Corporation Promoting axon regeneration in the adult CNS through control of protein translation
WO2011044701A1 (en) 2009-10-16 2011-04-21 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
EP2773382A4 (en) 2011-11-01 2016-03-23 Childrens Medical Center SIMULTANEOUS ACTIVATION OF MTOR AND STAT3 PATHS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
RU2015101100A (ru) 2012-06-15 2016-08-10 Фаундейшн Фор Байомедикал Рисерч Энд Инновейшн Профилактическое и/или терапевтическое средство для умеренного когнитивного нарушения
JP2016040542A (ja) * 2014-08-13 2016-03-24 学校法人金沢医科大学 認知症治療薬または認知症治療薬候補物質のスクリーニング方法
JP2017070404A (ja) * 2015-10-06 2017-04-13 アンディ チャオ トイレ床面の清潔な芳香パッド
WO2017199755A1 (ja) * 2016-05-19 2017-11-23 国立研究開発法人国立循環器病研究センター 認知症の予防及び／又は治療のための薬剤
WO2021230131A1 (ja) * 2020-05-11 2021-11-18 株式会社島津製作所 軽度認知障害治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277479A (en) * 1978-09-01 1981-07-07 Otsuka Pharmaceutical Co., Ltd. Tetrazolylalkoxycarbostyril derivatives and pharmaceutical compositions containing them
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649378A (en) * 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
JPH0653666B2 (ja) 1990-10-22 1994-07-20 大塚製薬株式会社 ヒトの糖尿病性知覚障害および末梢神経障害の治療剤
JPH0614444A (ja) * 1992-06-25 1994-01-21 Central Japan Railway Co 電力ケーブル接続部の固定装置
JPH06239745A (ja) * 1992-12-24 1994-08-30 Otsuka Pharmaceut Co Ltd 乾癬治療剤
AU5715994A (en) * 1992-12-24 1994-07-19 Otsuka Pharmaceutical Co., Ltd. Psoriasis remedy
JPH0776584A (ja) 1993-09-07 1995-03-20 Otsuka Pharmaceut Co Ltd 内皮細胞障害抑制剤
JP3944257B2 (ja) 1995-12-07 2007-07-11 大塚製薬株式会社 肝実質細胞増殖因子産生増加剤
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
MXPA00010254A (es) * 1998-05-01 2002-08-06 R Cutler Neal Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6257985B1 (en) * 1999-10-01 2001-07-10 Rexnord Corporation Global shaft coupling
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
JP4159224B2 (ja) 2000-02-29 2008-10-01 三洋電機株式会社 食器洗浄機
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277479A (en) * 1978-09-01 1981-07-07 Otsuka Pharmaceutical Co., Ltd. Tetrazolylalkoxycarbostyril derivatives and pharmaceutical compositions containing them
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
全文.

Also Published As

Publication number Publication date
US8329731B2 (en) 2012-12-11
DE602004003348T2 (de) 2007-05-31
CN101829116B (zh) 2015-11-25
CN101829116A (zh) 2010-09-15
US20060154963A1 (en) 2006-07-13
BRPI0407832A (pt) 2006-02-14
DE602004003348D1 (de) 2007-01-04
JP4590397B2 (ja) 2010-12-01
TW200501954A (en) 2005-01-16
AR043379A1 (es) 2005-07-27
AU2004216340A1 (en) 2004-09-10
WO2004075897A1 (en) 2004-09-10
JP2010285456A (ja) 2010-12-24
CY1106294T1 (el) 2011-10-12
KR20050098960A (ko) 2005-10-12
ES2276282T3 (es) 2007-06-16
PT1599205E (pt) 2007-01-31
CN1780623A (zh) 2006-05-31
MY136863A (en) 2008-11-28
JP2006518732A (ja) 2006-08-17
JP2013082735A (ja) 2013-05-09
CA2515590C (en) 2011-09-13
MXPA05008996A (es) 2005-10-18
JP5566482B2 (ja) 2014-08-06
JP5208172B2 (ja) 2013-06-12
KR101031163B1 (ko) 2011-04-27
US7825130B2 (en) 2010-11-02
CA2515590A1 (en) 2004-09-10
TWI323660B (en) 2010-04-21
DK1599205T3 (da) 2007-03-26
HK1091409A1 (en) 2007-01-19
EP1599205A1 (en) 2005-11-30
US8653104B2 (en) 2014-02-18
ATE345800T1 (de) 2006-12-15
EP1599205B1 (en) 2006-11-22
AU2004216340B9 (en) 2008-09-18
HK1148225A1 (zh) 2011-09-02
US20130065921A1 (en) 2013-03-14
US20100113515A1 (en) 2010-05-06
AU2004216340B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
CN1780623B (zh) Pten抑制剂或maxi-k通道开放剂
AU2019388843B2 (en) An Aurora A kinase inhibitor for use in the treatment of neuroblastoma
Danko et al. The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy
Carr et al. Evidence of increased dopamine receptor signaling in food-restricted rats
Raben et al. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten
MX2008016253A (es) Moduladores de metabolismo y el tratamiento de trastornos relacionados con el.
US8334262B2 (en) Cognitive function
BR112016000565B1 (pt) Polipeptídeo cíclico, seu uso, composição farmacêutica e processo para produzir a mesma
JP2012530759A (ja) アセナピンを含有する注射可能な配合物およびそれを用いた処置方法
WO2024153061A1 (zh) 诺米林及含其的组合物的应用
ITMI980086A1 (it) Composti pirimidin 3-ossido per il trattamento delle patologie muscolo-scheletriche in particolare per il trattamento della
TWI298068B (en) Pharmaceutical composition for schizophrenia
HK1148225B (en) Pten inhibitor or maxi-k channel opener
Ohmori et al. Eosinophil peroxidase deficiency in New Zealand white mice
Manning Synaptic zinc transporters support normal synapse structure and function in mouse auditory cortex
CN115804767A (zh) 苜蓿素在制备治疗/预防帕金森病的药物中的应用
Kenny et al. Effects of a single oral dose of 3-cyano-imipramine on serotonin uptake and content of platelets in healthy volunteers
EP1142583A1 (en) Antitumor agents
TW200815381A (en) Methods for treating or reducing muscle fatigue

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1091409

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1091409

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110914

CF01 Termination of patent right due to non-payment of annual fee